Rize Oncology Statistics

Total Valuation

Rize Oncology has a market cap or net worth of CAD 1.51 million. The enterprise value is -157,047.

Market Cap	1.51M
Enterprise Value	-157,047

Important Dates

The next estimated earnings date is Friday, May 23, 2025.

Earnings Date	May 23, 2025
Ex-Dividend Date	n/a

Share Statistics

Rize Oncology has 75.74 million shares outstanding. The number of shares has decreased by -16.52% in one year.

Current Share Class	75.74M
Shares Outstanding	75.74M
Shares Change (YoY)	-16.52%
Shares Change (QoQ)	n/a
Owned by Insiders (%)	87.97%
Owned by Institutions (%)	n/a
Float	9.11M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	n/a
PB Ratio	0.95
P/TBV Ratio	0.95
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	0.20
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 14.35

Current Ratio	14.35
Quick Ratio	13.98
Debt / Equity	n/a
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	n/a

Financial Efficiency

Return on equity (ROE) is -44.40% and return on invested capital (ROIC) is -29.67%.

Return on Equity (ROE)	-44.40%
Return on Assets (ROA)	-28.28%
Return on Invested Capital (ROIC)	-29.67%
Return on Capital Employed (ROCE)	-53.10%
Revenue Per Employee	n/a
Profits Per Employee	n/a
Employee Count	n/a
Asset Turnover	n/a
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -55.56% in the last 52 weeks. The beta is 2.49, so Rize Oncology's price volatility has been higher than the market average.

Beta (5Y)	2.49
52-Week Price Change	-55.56%
50-Day Moving Average	0.07
200-Day Moving Average	0.07
Relative Strength Index (RSI)	5.23
Average Volume (20 Days)	3,458

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

Revenue	n/a
Gross Profit	n/a
Operating Income	-847,517
Pretax Income	-792,687
Net Income	-792,687
EBITDA	n/a
EBIT	-847,517
Earnings Per Share (EPS)	-0.02

Full Income Statement

Balance Sheet

The company has 1.67 million in cash and n/a in debt, giving a net cash position of 1.67 million or 0.02 per share.

Cash & Cash Equivalents	1.67M
Total Debt	n/a
Net Cash	1.67M
Net Cash Per Share	0.02
Equity (Book Value)	1.60M
Book Value Per Share	0.04
Working Capital	1.60M

Full Balance Sheet

Cash Flow

Operating Cash Flow	-670,399
Capital Expenditures	n/a
Free Cash Flow	n/a
FCF Per Share	n/a

Full Cash Flow Statement

Margins

Gross Margin	n/a
Operating Margin	n/a
Pretax Margin	n/a
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

Rize Oncology does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	16.52%
Shareholder Yield	16.52%
Earnings Yield	-52.33%
FCF Yield	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Altman Z-Score	n/a
Piotroski F-Score	n/a